Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG004 in Acute Incomplete Cervical Spinal Cord Injury
NCT07840196Phase 1Recruiting
- Sponsor
- NovaGo Therapeutics
- Start
- Aug 2026
- Primary completion
- Jul 2029
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial in spinal cord injury (SCI) comparing NG004 with Placebo (2 arms). Primary endpoint: Adverse Events at 6 months. Started Aug 2026; status: recruiting.
02
Drugs
NG004
03
Conditions
spinal cord injury (SCI)
Beyond the preview
Go deeper on NCT07840196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07840196.